top of page
Writer's pictureIICCI_Communications

India needs to diversify pharma raw material imports, up R&D spends: RBI paper

The Covid-19 pandemic has been a "stress test" for the Indian pharma industry, and exposed its high dependence on imported raw materials and "surprisingly low" research and development efforts, a paper in RBI's July bulletin said on Thursday. "The high import dependency and surprisingly low R&D intensity of exports in the Indian pharmaceutical sector call for timely diversification of source countries for importing raw materials so as to mitigate potential supply-side bottlenecks," the paper by Shibanjan Dutta and Dhirendra Gajbhiye said.



It said the country is the third largest pharma manufacturer in the world by volume and fourteenth by value, and the sector contributes 2 per cent of Indian GDP and 8 per cent of the total merchandise exports.


The pandemic has perhaps been the "greatest stress test" for the pharmaceutical industry in the current century but the country's exports rose 21 per cent.


Apart from securing own supply chain, the country can also use the pandemic to elevate the sector's position in the global supply chain by standing as a reliable exporter of pharmaceuticals, it said.


The focus on finished formulations in the last two decades had resulted in negligence of in-house manufacture of APIs. This led to an increased reliance on China in particular, with estimates of API imports reaching as high as 85 per cent, it said.


"The upsurge in imports from China point towards China's large capacities (which are built up by the government and managed by private industry) and India's liberal approach in approving registrations for Chinese products," it said, citing a 2018 paper.


The paper said empirical results using panel data estimation of 42 pharmaceutical firms over the period 2007 to 2019 suggests that import intensity and research and development (R&D) expenditure are the two key determinants of export intensity.


"A strategy to diversify sources of imported inputs and incentivising R&D expenditure may be necessary to boost India's exports competitiveness further," it said.



 


Credit: ET

28 views5 comments

5 Comments



MZKO QPFQ
MZKO QPFQ
11 hours ago

무료카지노 무료카지노;

무료카지노 무료카지노;

google 优化 seo技术+jingcheng-seo.com+秒收录;

Fortune Tiger Fortune Tiger;

Fortune Tiger Fortune Tiger;

Fortune Tiger Slots Fortune…

站群/ 站群

gamesimes gamesimes;

03topgame 03topgame

EPS Machine EPS Cutting…

EPS Machine EPS and…

EPP Machine EPP Shape…

Fortune Tiger Fortune Tiger;

EPS Machine EPS and…

betwin betwin;

777 777;

slots slots;

Fortune Tiger Fortune Tiger;

Like

CBKM BOCU
CBKM BOCU
Oct 27

EPS Machine EPS Cutting…

EPS Machine Eps Raw…

EPS Machine EPS Recycling…

EPS Machine EPS Mould;

EPS Machine EPS Block…

EPP Machine EPP Shape…

EPTU Machine ETPU Moulding…

EPS Machine Aging Silo…

EPTU Machine ETPU Moulding…

EPS Machine EPS and…

EPS Machine EPS and…

AEON MINING AEON MINING

AEON MINING AEON MINING

KSD Miner KSD Miner

KSD Miner KSD Miner

BCH Miner BCH Miner

BCH Miner BCH Miner

Like

CBKM BOCU
CBKM BOCU
Oct 26

EPS Machine EPS Cutting…

EPS Machine Eps Raw…

EPS Machine EPS Recycling…

EPS Machine EPS Mould;

EPS Machine EPS Block…

EPP Machine EPP Shape…

EPTU Machine ETPU Moulding…

EPS Machine Aging Silo…

EPTU Machine ETPU Moulding…

EPS Machine EPS and…

EPS Machine EPS and…

AEON MINING AEON MINING

AEON MINING AEON MINING

KSD Miner KSD Miner

KSD Miner KSD Miner

BCH Miner BCH Miner

BCH Miner BCH Miner

Like

The COVID-19 pandemic has served as an "iq test free" for India's pharmaceutical industry, exposing its heavy reliance on imported raw materials and surprisingly low R&D efforts. This high import dependence and lackluster innovation intensity in exports call for urgent diversification of supply sources to mitigate potential disruptions.

Like
bottom of page